Multiplex Assays Market

Multiplex Assays Market by Product & Service (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma, Hospitals) - Global Forecast to 2027

Report Code: MD 4473 Apr, 2023, by marketsandmarkets.com

The global multiplex assays market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach $5.3 billion by 2027, growing at a CAGR of 8.8% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The need for automated and efficient systems in laboratories has grown, as conventional methods for testing are inadequate. This provides opportunities for the adoption of multiplex assays, with their potential for automation, convenience, accuracy, and reproducibility. Bead-based microplate assays provide a greater surface area for binding with lower background signals than traditional ELISA, while the beads can be coded and used in multiplex assays, which measure multiple analytes in a single-microplate well to reduce the overall cost and time per assay.

Attractive Opportunities in the Multiplex Assays Market

Multiplex Assays Market

To know about the assumptions considered for the study, Request for Free Sample Report

Multiplex Assays Market

Multiplex Assays Market Dynamics

DRIVER: Increasing advantages of multiplex assays over singleplex and traditional assays

As the name suggests, singleplex assays can only handle a single test at a time and require a higher sample volume. In multi-analyte studies, they need to be repeated for each analyte using new reagents and fresh samples, which increases the time taken and the costs incurred, and this also renders the process inefficient. In contrast, multiplex assays can handle several analytes simultaneously. The speed and efficacy of multiplex assays make them more adaptable for automation. In addition, their high throughput, accuracy, and reproducibility have also driven their adoption.

OPPORTUNITY: Increased focus on the need for high-throughput and automated systems

Of the various economic and regulatory impacts on the global healthcare industry, a major impact felt by the industry is the rising pressure for healthcare cost reduction. The Clinical Laboratory Fee Schedule (CLFS) was reformed under the Protecting Access to Medicare Act of 2014 (PAMA), which led to stringent inspection over test fees charged by laboratories and the actual cost of the test incurred by laboratories. This resulted in a reduction in clinical lab fees, affecting the fund flow of laboratories. In turn, laboratories need to maintain this fund flow by increasing the volume of tests but not compromising on the quality of tests. Moreover, laboratories are unable to serve the rapidly growing patient population owing to inadequate human resources.

Due to these challenges, the need for automated and efficient systems in laboratories has grown, as conventional methods for testing are inadequate.

RESTRAINT: Rising costs of equipment

While multiplex technology substantially saves operational costs and time, the initial investment in multiplex assay equipment is high. Despite long-term savings and advantages, the initial investment costs may restrain the small-scale use of multiplex assays to a certain extent. The variable costs of the reagents needed, and those fixed by the suppliers thereof, add to the overall expenditure. Furthermore, maintenance and insurance, laboratory supervision, and overhead costs (including utilities, space, and administration) are also additional expenses. As a result, high instrument cost is a major factor limiting the wider adoption of multiplex assays.

CHALLENGE: Increasing dearth of skilled professionals

The increase in the dearth of a skilled workforce has been a challenge for several decades, resulting in the rise of an aging workforce and declining enrolment in training programs. It takes almost five to ten years of continuous practice in clinical laboratory work for technicians to gain expertise. Europe and the UK have already reported low numbers of clinical technicians.

Consumables segment accounted for the largest share of the multiplex assays market, by product & service

The market is segmented into consumables, instruments, and software & services based on product & service. The consumables segment accounted for the largest share of the market in 2022, mainly due to the recurrent purchase of consumables for increasing research & clinical diagnostic applications.

In 2022, protein multiplex assays segment accounted for the largest share in the multiplex assays market, by type

The market is segmented into protein, nucleic acid, and cell-based multiplex assays by type. In 2022, the protein multiplex assays segment accounted for largest share of the market, mainly due to the increased usage of protein-based assays for biomarker research and clinical diagnostics.

In 2022, pharmaceutical & biotechnology companies segment accounted for the largest share in the multiplex assays market, by end user

The market is segmented into pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories, and other end users. In 2022, the pharmaceutical & biotechnology segment accounted for the largest share of the market. Multiplex assays are widely used in the pharmaceutical industry for clinical pharmacokinetics and bioequivalence studies in drug discovery. This can be attributed to the inherent specificity, high throughput, and high sensitivity offered by immunoassays for a wide range of analytes in biological samples.

North America is the largest regional market for multiplex assays market in 2022

The global market has been segmented into four major regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW). In 2022, North America accounted for the largest share of 45.1% of the global market, followed by Europe with a share of 27.8%. The high burden of infections and cancers on regional healthcare systems is another major driver for market growth. Furthermore, the presence of a well-developed healthcare infrastructure and the growing adoption of advanced technologies for cancer testing and infectious disease testing are other factors anticipated to support the growth of the market in the region. Over the years, healthcare spending in North America has increased at a significant rate. National health spending is projected to grow at an average annual rate of 5.4% during 2019–2028 and reach USD 6.2 trillion by 2028 (Source: Centers for Medicare & Medicaid Services). The growing healthcare expenditure is also one of the major drivers for the biotechnology sector.

Multiplex Assays Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), and DiaSorin S.p.A. (Italy). These players lead the market because of their extensive product portfolios and wide geographic presence. These dominant market players also have numerous advantages, such as more robust marketing and distribution networks, larger budgets for R&D, and better brand recognition.

Multiplex Assays Market Report Scope

Report Metrics

Details

Market Revenue in 2022

$3.5 billion

Projected Revenue in 2027

$5.3 billion

Revenue Rate

Poised to grow at a CAGR of 8.8%

Market Driver

Increasing advantages of multiplex assays over singleplex and traditional assays

Market Opportunity

Increased focus on the need for high-throughput and automated systems

This report categorizes the advanced wound care market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Consumables
  • Instruments
  • Software & Services

By Type

  • Protein Multiplex Assays
    • Planar Protein Assays
    • Bead-based Protein Assays
    • Other Protein Assays
  • Nucleic Acid Multiplex Assays
    • Planar Nucleic Acid Assays
    • Bead-based Nucleic Acid Assays
    • Other Nucleic Acid Assays
  • Cell-based Multiplex Assays

By Technology

  • Flow Cytometry
  • Fluorescence Detection
  • Luminescence
  • Multiplex Real-time PCR
  • Other Technologies

By Application

  • Research & Development
    • Drug Discovery & Development
    • Biomarker Discovery & Validation
  • Clinical Diagnostics
    • Infectious Diseases
    • Cancer
    • Cardiovascular Diseases
    • Autoimmune Diseases
    • Nervous System Disorders
    • Metabolism & Endocrinology Disorders
    • Other Diseases

By End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Research Institutes
  • Reference Laboratories
  • Other End Users

By Region

  • North America
  • US
  • Canada
  • Europe
  • Asia Pacific
  • Rest of the World

Recent Developments

  • In September 2021, Bio-Rad Laboratories launched its Bio-Plex Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The panels are for research use only (RUO).
  • In September, DiaSorin S.p.A. received the CE mark approval for its Simplexa COVID-19 & Flu A/B Direct kit, a multiplex test for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, and influenza B virus from the same patient sample in one reaction well. The assay is designed for use on the LIAISON MDX and is run directly from nasopharyngeal swabs (NPS) without the need for offboard extraction.
  • In August 2021, Becton, Dickinson and Company launched its new and fully automated high-throughput diagnostic system, BD COR System. The system uses robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the US.
  • In July 2021, DiaSorin S.p.A. acquired the leading company of multiplex assays, Luminex Corporation, for a price of USD 37.00 per share, that corresponds to a total equity value of approximately USD 1.8 billion.
  • In February 2021, Thermo Fisher Scientific acquired Mesa Biotech, a privately-held point-of-care molecular diagnostic company. This acquisition strengthened Thermo Fisher's operational excellence, access to raw materials, and existing distribution & sales channels with Mesa's innovative platform with a diverse array of diagnostic products, such as Accula System by Mesa Biotech that is dedicated to COVID-19 testing.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 REGIONAL SCOPE
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 UNITS CONSIDERED 
    1.6 LIMITATIONS 
    1.7 STAKEHOLDERS 
    1.8 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 LIMITATIONS 
    2.8 GROWTH RATE ASSUMPTIONS 
    2.9 RISK ASSESSMENT 
           2.9.1 RISK ASSESSMENT: MARKET
    2.10 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 8 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 MULTIPLEX ASSAYS MARKET OVERVIEW 
          FIGURE 14 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH
    4.2 MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027 
          FIGURE 15 CONSUMABLES PRODUCT & SERVICE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
    4.3 MARKET SHARE, BY TYPE, 2022 VS. 2027 
          FIGURE 16 PROTEIN MULTIPLEX ASSAYS TYPE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
    4.4 MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027 
          FIGURE 17 FLOW CYTOMETRY TECHNOLOGY TO ACCOUNT FOR LARGEST MARKET SHARE
    4.5 MARKET SHARE, BY APPLICATION, 2022 VS. 2027 
          FIGURE 18 RESEARCH & DEVELOPMENT APPLICATION TO ACCOUNT FOR LARGER MARKET SHARE
    4.6 MARKET SHARE, BY END USER, 2022 VS. 2027 
          FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES END USER SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
    4.7 MARKET: REGIONAL GROWTH OPPORTUNITIES 
          FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 55)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing use of multiplex assays in companion diagnostics
                    5.2.1.2 Increasing advantages over singleplex and traditional assays
                    5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
                                FIGURE 22 INCIDENCE OF DIABETES, BY REGION, IN 2021, 2030, AND 2045
                                TABLE 1 TOTAL HEALTH EXPENDITURE DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY
                                TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
                                TABLE 3 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR DIAGNOSIS OF SARS-COV-2
           5.2.2 RESTRAINTS
                    5.2.2.1 Rising costs of equipment
                    5.2.2.2 Growing number of stringent regulations and standards
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics
                    5.2.3.2 Rising need for high-throughput and automated systems
           5.2.4 CHALLENGES
                    5.2.4.1 Increasing dearth of skilled professionals
                                TABLE 4 NUMBER OF LAB TECHNOLOGISTS AND TECHNICIANS IN US, 2020
    5.3 CUSTOMIZATION DATA 
          TABLE 5 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
 
6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE (Page No. - 63)
    6.1 INTRODUCTION 
          TABLE 6 MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
    6.2 PRIMARY NOTES 
           6.2.1 KEY INDUSTRY INSIGHTS
    6.3 CONSUMABLES 
           6.3.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
                    TABLE 7 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 8 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 INSTRUMENTS 
           6.4.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
                    TABLE 9 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 SOFTWARE & SERVICES 
           6.5.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
                    TABLE 11 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 12 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 MULTIPLEX ASSAYS MARKET, BY TYPE (Page No. - 69)
    7.1 INTRODUCTION 
          TABLE 13 MARKET, BY TYPE, 2020–2027 (USD MILLION)
    7.2 PROTEIN MULTIPLEX ASSAYS 
          TABLE 14 MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 15 MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 16 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.1 PLANAR PROTEIN ASSAYS
                    7.2.1.1 Pivotal role in drug discovery to support uptake
                                TABLE 17 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 18 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.2 BEAD-BASED PROTEIN ASSAYS
                    7.2.2.1 Best suited to study protein-protein interactions
                                TABLE 19 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 20 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.3 OTHER PROTEIN ASSAYS
                    TABLE 21 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 22 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 NUCLEIC ACID MULTIPLEX ASSAYS 
          TABLE 23 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA AND SARS-COV-2
          TABLE 24 MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 25 MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 26 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.1 PLANAR NUCLEIC ACID ASSAYS
                    7.3.1.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
                                TABLE 27 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 28 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS
                    7.3.2.1 Increasing infectious diseases and genetic screening tests to drive market
                                TABLE 29 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 30 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.3 OTHER NUCLEIC ACID ASSAYS
                    TABLE 31 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 32 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 CELL-BASED MULTIPLEX ASSAYS 
           7.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
                    TABLE 33 MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 34 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY (Page No. - 82)
    8.1 INTRODUCTION 
          TABLE 35 MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    8.2 FLOW CYTOMETRY 
           8.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO MAKE THIS MARKET SEGMENT LARGEST
                    TABLE 36 MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 37 NORTH AMERICA: MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 FLUORESCENCE DETECTION 
           8.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL GROWTH
                    TABLE 38 MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 39 NORTH AMERICA: MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 LUMINESCENCE 
           8.4.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
                    TABLE 40 MARKET FOR LUMINESCENCE, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 41 NORTH AMERICA: MARKET FOR LUMINESCENCE, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 MULTIPLEX REAL-TIME PCR 
           8.5.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
                    TABLE 42 MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 43 NORTH AMERICA: MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2020–2027 (USD MILLION)
    8.6 OTHER TECHNOLOGIES 
          TABLE 44 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
          TABLE 45 NORTH AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 MULTIPLEX ASSAYS MARKET, BY APPLICATION (Page No. - 89)
    9.1 INTRODUCTION 
          TABLE 46 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    9.2 RESEARCH & DEVELOPMENT 
          TABLE 47 MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 48 MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
          TABLE 49 NORTH AMERICA: MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
           9.2.1 DRUG DISCOVERY & DEVELOPMENT
                    9.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
                                TABLE 50 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 51 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
           9.2.2 BIOMARKER DISCOVERY & VALIDATION
                    9.2.2.1 Multiplex assays aid in quantitative measurement of protein biomarkers in large samples
                                TABLE 52 MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 53 NORTH AMERICA: MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 CLINICAL DIAGNOSTICS 
          TABLE 54 MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 55 MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 56 NORTH AMERICA: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.1 INFECTIOUS DISEASES
                    9.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
                                TABLE 57 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 58 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.2 CANCER
                    9.3.2.1 Rising burden of cancer to drive market
                                TABLE 59 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                                TABLE 60 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
                                TABLE 61 MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 62 NORTH AMERICA: MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.3 CARDIOVASCULAR DISEASES
                    9.3.3.1 High burden of cardiovascular diseases to support market growth
                                TABLE 63 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 64 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.4 AUTOIMMUNE DISEASES
                    9.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
                                TABLE 65 PREVALENCE OF SOME AUTOIMMUNE DISEASES
                                TABLE 66 MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 67 NORTH AMERICA: MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.5 NERVOUS SYSTEM DISORDERS
                    9.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
                                TABLE 68 MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 69 NORTH AMERICA: MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
                    9.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers that help in timely diagnosis of such conditions
                                TABLE 70 MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 71 NORTH AMERICA: MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.7 OTHER DISEASES
                    TABLE 72 MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 73 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 MULTIPLEX ASSAYS MARKET, BY END USER (Page No. - 105)
     10.1 INTRODUCTION 
             TABLE 74 MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             10.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE ITS UPTAKE
                        TABLE 75 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                        TABLE 76 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
     10.3 HOSPITALS & RESEARCH INSTITUTES 
             10.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
                        TABLE 77 MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
                        TABLE 78 NORTH AMERICA: MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
     10.4 REFERENCE LABORATORIES 
             10.4.1 GROWING NUMBER OF CLINICAL TESTS PERFORMED IN REFERENCE LABORATORIES AND INCREASING NUMBER OF ACCREDITED LABORATORIES TO SUPPORT MARKET GROWTH
                        TABLE 79 MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
                        TABLE 80 NORTH AMERICA: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
     10.5 OTHER END USERS 
             TABLE 81 MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
             TABLE 82 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
 
11 MULTIPLEX ASSAYS MARKET, BY REGION (Page No. - 112)
     11.1 INTRODUCTION 
             TABLE 83 MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 NORTH AMERICA 
             TABLE 84 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 85 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 86 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 87 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 88 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 89 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             FIGURE 23 NORTH AMERICA: MARKET SNAPSHOT
             11.2.1 RECESSION IMPACT ON NORTH AMERICA
             11.2.2 US
                        11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
                                      TABLE 90 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 91 US: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 92 US: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 93 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 94 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Increased funding activities by government in life sciences research & drug development to support market growth
                                      TABLE 95 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 96 CANADA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 97 CANADA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 98 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 99 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.3 EUROPE 
             TABLE 100 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
             TABLE 101 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 102 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 103 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 104 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 105 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.1 RECESSION IMPACT ON EUROPE
     11.4 ASIA PACIFIC 
             FIGURE 24 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET SNAPSHOT
             TABLE 106 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 107 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 108 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 109 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 110 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.1 RECESSION IMPACT ON ASIA PACIFIC
     11.5 REST OF THE WORLD 
             TABLE 111 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 112 REST OF THE WORLD: MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 113 REST OF THE WORLD: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 114 REST OF THE WORLD: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 115 REST OF THE WORLD: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.1 RECESSION IMPACT ON REST OF THE WORLD
 
12 COMPETITIVE LANDSCAPE (Page No. - 133)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
                        TABLE 116 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES
     12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2017–2021)
     12.4 MARKET SHARE ANALYSIS 
             12.4.1 MULTIPLEX ASSAYS MARKET
                        FIGURE 26 MARKET SHARE, BY KEY PLAYER, 2021
                        TABLE 117 MARKET: INTENSITY OF COMPETITIVE RIVALRY
     12.5 COMPANY EVALUATION QUADRANT 
             12.5.1 LIST OF EVALUATED VENDORS
             12.5.2 STARS
             12.5.3 EMERGING LEADERS
             12.5.4 PERVASIVE PLAYERS
             12.5.5 PARTICIPANTS
                        FIGURE 27 MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
     12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021) 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 28 MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
     12.7 COMPETITIVE SCENARIO 
             12.7.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
                        TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020- 2023)
             12.7.2 DEALS
                        TABLE 119 KEY DEALS (2020-2023)
 
13 COMPANY PROFILES (Page No. - 143)
     13.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View)*
             13.1.1 ILLUMINA, INC.
                        TABLE 120 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 29 COMPANY SNAPSHOT: ILLUMINA, INC. (2022)
             13.1.2 BIO-RAD LABORATORIES, INC.
                        TABLE 121 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2022)
             13.1.3 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 122 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 31 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC. (2021)
             13.1.4 BECTON, DICKINSON AND COMPANY
                        TABLE 123 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW
                        FIGURE 32 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2022)
             13.1.5 DIASORIN S.P.A.
                        TABLE 124 DIASORIN S.P.A.: BUSINESS OVERVIEW
                        FIGURE 33 COMPANY SNAPSHOT: DIASORIN S.P.A. (2021)
             13.1.6 QIAGEN N.V.
                        TABLE 125 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2021)
             13.1.7 ABCAM PLC
                        TABLE 126 ABCAM PLC.: BUSINESS OVERVIEW
                        FIGURE 35 COMPANY SNAPSHOT: ABCAM PLC (2021)
             13.1.8 MERCK KGAA
                        TABLE 127 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2022)
             13.1.9 AGILENT TECHNOLOGIES, INC.
                        TABLE 128 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 37 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2022)
             13.1.10 QUANTERIX
                        TABLE 129 QUANTERIX: BUSINESS OVERVIEW
                        FIGURE 38 COMPANY SNAPSHOT: QUANTERIX (2022)
             13.1.11 BIO-TECHNE
                        TABLE 130 BIO-TECHNE: BUSINESS OVERVIEW
                        FIGURE 39 COMPANY SNAPSHOT: BIO-TECHNE (2021)
             13.1.12 MESO SCALE DIAGNOSTICS, LLC
                        TABLE 131 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
             13.1.13 RANDOX LABORATORIES LTD.
                        TABLE 132 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 OLINK
                        TABLE 133 OLINK: COMPANY OVERVIEW
             13.2.2 SEEGENE INC.
                        TABLE 134 SEEGENE INC.: COMPANY OVERVIEW
             13.2.3 SIEMENS HEALTHINEERS AG
                        TABLE 135 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
             13.2.4 PERKINELMER INC.
                        TABLE 136 PERKINELMER INC.: COMPANY OVERVIEW
             13.2.5 SHIMADZU CORPORATION
                        TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
             13.2.6 PROMEGA CORPORATION
                        TABLE 138 PROMEGA CORPORATION: COMPANY OVERVIEW
             13.2.7 ENZO BIOCHEM INC.
                        TABLE 139 ENZO BIOCHEM INC.: COMPANY OVERVIEW
             13.2.8 CAYMAN CHEMICAL
                        TABLE 140 CAYMAN CHEMICAL: COMPANY OVERVIEW
             13.2.9 BOSTER BIOLOGICAL TECHNOLOGY
                        TABLE 141 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
             13.2.10 ANTIGENIX AMERICA, INC.
                        TABLE 142 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW
             13.2.11 QUANSYS BIOSCIENCES INC.
                        TABLE 143 QUANSYS BIOSCIENCES INC.: COMPANY OVERVIEW
             13.2.12 RAYBIOTECH LIFE, INC.
                        TABLE 144 RAYBIOTECH LIFE, INC.: COMPANY OVERVIEW
 
14 APPENDIX (Page No. - 200)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

The objective of the study is analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the multiplex assays market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were use to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants

Multiplex Assays Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2021/2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

COMPANY NAME

DESIGNATION

Illumina, Inc.

Marketing Manager

Bio-Rad Laboratories Inc.

Senior Product Manager

Thermo Fisher Scientific, Inc.

General Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the multiplex assays market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the multiplex assays market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Multiplex Assays Market Size: Botton Up Approach

Multiplex Assays Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global multiplex assays market Size: Top-Down Approach

IoT in Smart Cities Market Size, and Share

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Multiplex assays are analytical tools used to measure multiple analytes qualitatively and quantitatively from biological samples in a single run. Multiplex assays are faster, and they can be automated to a higher degree and use comparatively less sample volume than singleplex assays.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To provide detailed information regarding the major factors influencing the market growth (such as (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall multiplex assays market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four regions: North America, Europe, the Asia Pacific, and the Rest of the World
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as product launches, regulatory approvals, agreements, partnerships, collaborations, and acquisitions in the multiplex assays market
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

MarketsandMarkets offers the following customizations for this market report

Country Information

  • Additional country-level analysis of the multiplex assays market

Company profiles

  • Additional five company profiles of players operating in the multiplex assays market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the multiplex assays market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4473
Published ON
Apr, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Multiplex Assays Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback